MIMEDX GROUP, INC. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 62/100
What the filing says
MIMEDX reported Q3 2026 net sales of $62M (down 45% from $114M in Q3 2025), driven by a 71% decline in Wound sales due to January 2026 Medicare reimbursement cuts, partially offset by 9% Surgical growth. The company returned to positive Adjusted EBITDA of $2M (vs. $35M YoY), repaid its $17M term loan to reach zero debt, and maintains $121M cash. The pending Sanara MedTech acquisition ($350M enterprise value, 4.4M shares + $33/share cash) remains pending FTC clearance following a Second Request; Hayfin committed $300M financing at SOFR+625%. Separately, MIMEDX secured a $25M patent license settlement (five $5M annual installments) and won favorable FDA litigation remanding AXIOFILL classification.
Why this rating
Severe top-line collapse (45% YoY) and strategic deal uncertainty material to $719M market cap; partially offset by cost cuts, zero debt, and $121M cash strengthening balance sheet.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.